U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

As winter approaches, DuPage County Health Department is urging residents to be up-to-date on their flu, COVID, RSV and other ...

Pfizer (PFE) discontinues development of experimental RSV therapy sisunatovir from pipeline in a blow for its $525M ...

GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST ...

The UK High Court has ruled that two GSK respiratory syncytial virus (RSV) vaccine patents are invalid in an action involving ...

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and ...

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

Tata Motors' British luxury car unit, Jaguar Land Rover (JLR), reported a three percent decline in retail sales to 1,03,108 ...

The RSV vaccine is unequivocally recommended for adults who are residents in skilled nursing and assisted living facilities.

GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...